Anticancer activity of artemisinin-derived trioxanes

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 12, 2006, Pages 1665-1672

  Posner, Gary H ^a   D'Angelo, John ^a   O'Neill, Paul M ^b   Mercer, Amy ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Artemisinin; Dimers; Endoperoxides; Trioxanes

Indexed keywords

ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ARTEETHER; ARTEMETHER; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; DIHYDROARTEMISININ; DOXORUBICIN; FERROSANOL; FERROUS GLYCINE SULFATE; GEMCITABINE; HERBACEOUS AGENT; HOLOTRANSFERRIN; HYDROXYUREA; IRON DERIVATIVE; METHOTREXATE; MITOMYCIN; PACLITAXEL; TRANSFERRIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; HEARING LOSS; NEUROTOXICITY; PATENT; REVIEW; SCIENTIFIC LITERATURE; SOLID TUMOR; STRUCTURE ACTIVITY RELATION;

EID: 33845879363     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.12.1665     Document Type: Review

References (49)

1. WARHURST D: Drug resistance in Plasmodioum falciparum malaria. Infection (1999) 27:S55-S58.
2. LI Y, WU YL: An over four millennium story behind qinghaosu (artemisinin) - a fantastic antimalarial drug from a traditional chinese herb. Curr. Med. Chem. (2003) 10:2197-2230.
3. O'NEILL PM, POSNER GH: A medicinal chemistry perspective on artemisinin and related endoperoxides. J. Med. Chem. (2004) 47:2945-2964.
4. KAWABATA H, NAKAMAKI T, IKONOMI P, SMITH RD, GERMAIN RS, KOEFFLER HP: Expression of transferrin receptor 2 in normal and neoplastic hemaotpoietic cells. Blood (2001) 98:2714-2719.
5. LAI H, SINGH NP: Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett. (1995) 91:41-46.
6. WOERDENBAG HJ, MOSKAL TA, PRAS N et al.: Cytotoxicity of artemisinin-related endoperoxides to ehrlich ascites tumor cells. J. Nat. Prod. (1993) 56:849-856.
7. POSNER GH, PLOYPRADITH P. HAPANGAMA W et al.: Trioxane dimers have potent antimalarial, antiproliferative and antitumor activities in vitro. Bioorg. Med. Chem. (1997) 5:1257-1265.
8. BEEKMAN AC, BARENTSEN AR, WOERDENBAG HJ et al.: Stereochemistry-dependent cytotoxicity of some artemisinin derivatives. J. Nat. Prod. (1997) 60:325-330.
9. 1 phase of the cell cycle. Bioorg. Med. Chem. Lett. (2001) 11:5-8.
10. OH S, JEONG IH, AHN CM, SHIN W-S, LEE S: Synthesis and antiangiogenic activity of thioacetal artemisinin derivatives. Bioorg. Med. Chem. (2004) 12:3783-3790.
11. JEYADEVAN JP, BRAY PG, CHADWICK J et al.: Antimalarial and antitumor evaluation of novel C-10 non-acetal dimers of 10β(2-hydroxyethyl) deoxo-artemisinin. J. Med. Chem. (2004) 47:1290-1298.
12. LIU Y, WONG VK-W, KO BC-B, WONG M-K, CHE C-M: Synthesis and cytotoxicity studies of artemisinin derivatives containing lipophilic alkyl carbon chains. Org. Lett. (2005) 7(8):1561-1564.
13. POSNER GH, PLOYPRADITH P, PARKER MH et al.: Antimalarial, antiproliferative and antitumor activities of artemisinin-derived, chemically robust, trioxane dimers. J. Med. Chem. (1999) 42:4275-4280.
14. JUNG M, LEE S, HAM J, LEE K, KIM H, KIM SK: Antitumor activity of novel deoxoartemisinin monomers, dimers, and trimer. J. Med. Chem. (2003) 46:987-994.
15. POSNER GH, MCRINER AJ, PAIK I-H et al.: Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. J. Med. Chem. (2004) 47:1299-1301.
16. ALAGBALA AA, MCRINER AJ, BORSTNIK K et al.: Biological mechanisms of action of novel C-10 non-acetal trioxane dimers in prostate cancer cell lines. J. Med. Chem. In press.
17. BAEGE AC, POSNER GH: unpublished results.
18. EKTHAWATCHAI S, KAMCHONWONGPAISAN S, KONGSAEREE P, TARNCHOMPOO B, THEBTARANONTH Y, YUTHAVONG Y: C-16 artemisinin derivatives and their antimalarial and cytotoxic activities: syntheses of artemisinin monomers, dimers, trimers and tetramers by nucleophilic additions to artemisitene. J. Med. Chem. (2001) 44:4688-4695.
19. EFFERTH T, DUNSTAN H, SAUERBREY A, MIYACHI H, CHITAMBAR CR: The anti-malarial artesunate is also active against cancer. Int. J. Oncol. (2001) 18:767-773.
20. LAI HC, SINGH NP: Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett. (1995) 91:41-46.
21. KWOK JC, RICHARDSON DR: The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit. Rev. Oncol. Hematol. (2002) 42:65-78.
22. CHITAMBAR CR, SELIGMAN PA: Effects of different transferrin forms on transferrin receptor expression, iron uptake and cellular proliferation of human-leukemic HL60 cells - mechanisms responsible for the specific cytotoxicity of transferrin-gallium. J. Clin. Invest. (1986) 78:1538-1546.
23. LEBMAN D, TRUCCO M, BOTTERO L, LANGE B, PESSANO S, ROVERA G: A mAb that detects expression of transferrin receptor in human erythroid precursor cells. Blood (1982) 59:671-678.
24. SINGH NP, LAI HC: Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci. (2001) 70:49-56.
25. EFFERTH T, BENAKIS A, ROMERO MR et al.: Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Rad. Biol. Med. (2004) 37:998-1009.
26. KIM SJ, KIM MS, LEE JW et al.: Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. J. Cancer Res. Clin. Oncol. (2006) 132:129-135.
27. WU WM, YAO ZJ, WU YL et al.: Ferrous ion induced cleavage of the peroxy bond in qinghaosu and its derivatives and the DNA damage associated with this process. Chem. Comun. (1996) 18:2213-2214.
28. LI W, MO WK, SHEN D et al.: Yeast model uncovers dual roles of mitochondria in the action of artemisinin. PLOS Genetics (2005) 1:329-334.
29. SADAVA D, PHILLIPS T, LIN C, KANE SE: Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett. (2002) 179:151-156.
30. SINGH NP, LAI HC, Artemisinin induces apoptosis in human cancer cells. Anticancer Res. (2004) 24:2277-2280.
31. DISBROW GL, BAEGE AC, KIERPIEC KA et al.: Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelia] cells in vitro and in vivo. Cancer Res. (2005) 65:10854-10861.
32. SEARLE J, KERR JF, BISHOP CJ: Necrosis and apoptosis - distinct modes of cell-death with fundamentally different significance. Pathol. Annu. (1982) 17:229-259.
33. PARK BK, O'NEILL PM, MAGGS JL, PIRMOHAMED M: Safety assessment of peroxide antimalarials: clinical and chemical perspectives. Br. J. Clin. Pharmacol. (1998) 46:521-529.
34. CHEN HH, ZHOU HJ, FAN X: Inhibition of human cancer cell line growth and human umbilical vein endothetial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol. Res. (2003) 48:231-236.
35. DELL'EVA R, PFEFFER U, VENE R, et al.: Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochem. Pharm. (2004) 68:2359-2366.
36. CHEN HH, ZHOU HJ, WANG WQ, WU GD: Antimalarial dihydroartemisinin also inhibits angiogenesis. Cancer Chemo. Pharmacol. (2004) 53:423-432.
37. FOLKMAN J, BACH M, ROWE JW et al.: Tumor angiogenesis - therapeutic implications. NEJM (1971) 285:1182-1202.
38. CHEN HH, ZHOU HJ, WU GD, LOU XE: Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacol. (2004) 71:1-9.
39. LAI HC, SINGH NP: Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. Cancer Lett. (2006) 231:43-48.
40. BERGER TG, DIECKMANN D, EFFERTH T et al.: Artesunate in the treatment of metastatic uveal melanoma - first experiences. Oncol. Rep. (2005) 14:1599-1603.
41. PANOSSIAN LA, GARGA NI, PELLETIER D: Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Annal. Neurol. (2005) 58:812-813.
42. WHITE NJ, ASHLEY EA, NOSTEN F: Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Annal. Neurol. (2006) 59:725-726.
43. PARSONS M, PEPPER E, CHAN V et al.: Toxic brainstem encephalopathy after artemisinin treatment for breast cancer - reply. Annal. Neurol. (2006) 59:726-726.
44. BREWER TG, PEGGINS JO, GRATE SJ et al.: Neurotoxicity in animals due to arteether and artemecher. Trans. R. Soc. Trop. Med. Hyg. (1994) 88:33-36.
45. PETRAS JM, YOUNG GD, BAUMAN RA et al.: Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: the lateral reticular nuclei, paramedian reticular nuclei, and perihypoglossal nuclei. Anat. Embryol. (2000) 201:383-397.
46. TOOVEY S, JAMIESON A: Audiometric changes associated with the treatment of uncomplicated falciparum malaria with co-artemether. Trans. R. Soc. Trop. Med. Hyg. (2004) 98:261-267.
47. EFFERTH T, BRIEHL MM, TOME ME: Role of antioxidant genes for the activity of artesunate against tumor cells. Int. J. Oncol. (2003) 23:1231-1235.
48. EFFERTH T: Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Res. Updat. (2005) 8:85-97.
49. LAI H, SASAKI T, SINGH NP: Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds. Expert Opin. Ther. Targets (2005) 9:995-1007.